cold2184

Interesting. I've actually seen a couple of instances where ALT was slightly elevated in one particular animal group on a very high dose, but it normalized quickly. It was an outlier, though.

clinical21

My research has focused more on gut health, but we always include a full metabolic panel. BPC 157 seems to be quite gentle on the liver, which is a big plus when you are looking at systemic applications.

vialfiles38

I agree with the general consensus here. In my experience, BPC 157 is remarkably well tolerated from a hepatic perspective. It's one of the reasons it's so appealing for broad research applications.

echomind

That's a great point. I've seen some promising preclinical work on BPC 157 in models of chemically induced liver injury. It seems to mitigate some of the damage, which is very exciting.

cyclegal27

Thanks for the input so far! The slight elevation you mentioned is exactly the kind of nuance I'm looking for. Was that a chronic administration study or acute?

quietx74

I've run several protocols involving BPC 157 and haven't seen any significant negative impact on liver enzymes. If anything, in some models, there was a slight trend towards stabilization or even improvement, but nothing dramatic enough to call a definitive finding without more targeted research.

grayowl0

Yeah, I concur with that. My lab's data aligns. We monitor liver panels closely in our animal models, and BPC 157 has consistently shown a benign profile. No red flags at all.

cold2184

It was a longer term chronic administration, about 8 weeks. We hypothesized it might have been related to metabolic stress from other factors in that specific model, not directly BPC.

protocol21

Has anyone looked at it in models of existing liver damage? That would be the real test of its protective or regenerative potential, beyond just maintaining normal function.